Across TCGA pan-cancer cohorts, C1orf210 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C1orf210 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher C1orf210 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C1orf210 expression acts as an unfavorable survival marker.
CHOL are the cancer types where C1orf210 Mutation most reproducibly stratifies survival.